Cargotec will start to repurchase own shares

CARGOTEC CORPORATION, STOCK EXCHANGE RELEASE, 7 AUGUST 2024 AT 6:30 PM (EEST)

Cargotec will start to repurchase own shares

Cargotec Corporation's Board of Directors has decided to exercise the authorisation of the Annual General Meeting on 30 May 2024 to repurchase the company's own shares. Cargotec will repurchase 400,000 class B shares to be used as reward payments for Cargotec's share-based incentive programmes. The shares will be purchased at public trading on Nasdaq Helsinki Ltd. at the market price. The repurchases will start on 9 August 2024 at the earliest. According to the authorisation given to the Board of Directors by the Annual General Meeting, the maximum amount of shares that can be acquired is 952,000 class A shares and 5,448,000 class B shares.

On 7 August 2024, Cargotec held a total of 384,050 own class B shares.

Cargotec Corporation
The Board of Directors

For further information, please contact:
Mikko Puolakka, Executive Vice President and CFO, tel. +358 20 777 4000
Aki Vesikallio, Vice President, Investor Relations, tel. +358 40 729 1670

Cargotec’s (Nasdaq Helsinki: CGCBV) businesses Hiab and MacGregor enable smarter cargo flow for a better everyday with leading cargo handling solutions and services. Hiab is a leading provider of smart and sustainable on road load-handling solutions, committed to delivering the best customer experience every day with the most engaged people and partners. MacGregor is a leader in sustainable maritime cargo and load handling with a strong portfolio of products, services and solutions. The company's continuing operations sales in 2023 totalled approximately EUR 2.5 billion and it employs over 6,000 people. www.cargotec.com

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Appointment of Non-Executive Directors
• Zcash Price Prediction: ZEC Eyes $1,000 After 48% Surge as AlphaPepe Emerges in the Top AI Crypto Coin Race
• Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion